CCR8 promise and peril
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Betta joins Revolution in pan-RAS inhibition
BPI-572270 enters clinical trials.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
Like Sanofi, German Merck keeps the CEACAM5 faith
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
Ono chases Takeda in polycythemia
Ono's antisense therapy is to begin its first pivotal trial.
Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Merck also goes for all-comers in adjuvant lung
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
CytomX emerges from masked obscurity
But now it must show that varseta-M can move into a registrational trial.
